Lua Labs Report — Histones and aromatase in adipose tissue: the adipocyte as an endocrine organ

Date: 2026-06-29 Researcher: Lua Labs Classification: Epigenetics Line: L5 — Epigenetics and the perimenopausal window Subtopic: 5.3 — Histones and aromatase expression in adipose tissue: why fat tissue is an endocrine organ

External sources

Lee A, den Hartigh LJ. (2025). "Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan." Frontiers in Endocrinology. DOI: 10.3389/fendo.2025.1682231. https://pubmed.ncbi.nlm.nih.gov/41180177/
Ostinelli G, Laforest S, Denham SG, Gauthier MF, Drolet-Labelle V, Scott E, et al. (2022). "Increased Adipose Tissue Indices of Androgen Catabolism and Aromatization in Women With Metabolic Dysfunction." Journal of Clinical Endocrinology & Metabolism. DOI: 10.1210/clinem/dgac261. https://doi.org/10.1210/clinem/dgac261
Iyengar NM, Zhou XK, Gucalp A, Giri DD, Harbus MD, Falcone DJ, et al. (2017). "Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers." Journal of Clinical Endocrinology & Metabolism. DOI: 10.1210/jc.2016-3606. https://pmc.ncbi.nlm.nih.gov/articles/PMC5443335/
Vidal CM, Alva-Ornelas JA, Chen NZ, Senapati P, Tomsic J, Robles VM, et al. (2024). "Insulin Resistance in Women Correlates with Chromatin Histone Lysine Acetylation, Inflammatory Signaling, and Accelerated Aging." Cancers. DOI: 10.3390/cancers16152735. https://www.mdpi.com/2072-6694/16/15/2735
Wu R, Li F, Wang S, Jing J, Cui X, Huang Y, et al. (2025). "Epigenetic programming of estrogen receptor in adipocytes by high-fat diet regulates obesity-induced inflammation." JCI Insight. DOI: 10.1172/jci.insight.173423. https://insight.jci.org/articles/view/173423
Knower KC, To SQ, Simpson ER, Clyne CD. (2010). "Epigenetic mechanisms regulating CYP19 transcription in human breast adipose fibroblasts." Molecular and Cellular Endocrinology. DOI: 10.1016/j.mce.2010.02.035. https://doi.org/10.1016/j.mce.2010.02.035
Zhao Y, Nichols JE, Valdez R, Mendelson CR, Simpson ER. (1997). "Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture." Journal of Steroid Biochemistry and Molecular Biology. PMID: 9365191. https://pubmed.ncbi.nlm.nih.gov/9365191/
Bitirim CV, Aksoy ZB, Akcali KC. (2021). "Estrogen receptor alpha regulates the expression of adipogenic genes genetically and epigenetically in rat bone marrow-derived mesenchymal stem cells." PeerJ. DOI: 10.7717/peerj.12071. https://pubmed.ncbi.nlm.nih.gov/34595066/
Lankila H, Kekalainen T, Hietavala EM, Laakkonen EK. (2025). "A mediating role of visceral adipose tissue on the association of health behaviours and metabolic inflammation in menopause: a population-based cross-sectional study." Scientific Reports. DOI: 10.1038/s41598-025-85134-8. https://doi.org/10.1038/s41598-025-85134-8

Background knowledge

Adipose tissue is not a passive energy depot. It is an endocrine and immunometabolic organ containing adipocytes, preadipocytes, fibroblasts, endothelium, macrophages, lymphocytes, extracellular matrix, and sympathetic nerves. It produces leptin, adiponectin, resistin, cytokines, prostaglandins, free fatty acids, and steroids. In the peri/postmenopausal window its importance rises because the ovary reduces cyclic estradiol production, while adipose tissue maintains the capacity to convert adrenal and ovarian androgen precursors into estrones and estradiol through aromatase, encoded by CYP19A1.

Aromatase catalyzes the irreversible conversion of the A ring of C19 androgens into C18 estrogens: androstenedione to estrone (E1), and testosterone to estradiol (E2). In women with active cycles, the ovary dominates the E2 pulse. In postmenopause, adipose tissue, skin, muscle, and breast stroma weigh more in the local and systemic pool; the phenotype tends to be more E1-dominant because adrenal androstenedione is converted to estrone and E1/E2 interconversion depends on HSD17B isoenzymes. That shift is not trivial: E2 is a more potent agonist of ERα/ERβ in many tissues, while E1 may function as a reserve, weak signal, or discordant signal depending on receptor, adipose depot, inflammation, and metabolic state.

CYP19A1 is a gene with tissue-specific regulation through alternative promoters. In normal adipose tissue, promoter I.4 responds to glucocorticoids and cytokines through STAT-like elements; in inflamed breast adipose tissue or tissue adjacent to tumor, promoters I.3/II respond to PGE2/cAMP/PKA/PKC. This framework connects three biological layers: HPA/cortisol, inflammation/insulin, and estrogenic signaling. When the adipocyte becomes hypertrophic and insulin-resistant, it recruits macrophages, produces IL-6/TNFα/PGE2, activates NFκB/JAK-STAT, and creates a microenvironment that can induce local aromatase.

The epigenetic layer is the amplifier. Acetylated histones such as H3K9ac and H3K27ac open chromatin and facilitate inflammatory transcription; repressive marks such as H3K27me3 limit adipogenic programs. If adipose tissue combines open inflammatory chromatin, inducible CYP19A1, and silenced adipocyte ERα, an endocrine paradox appears: the tissue can produce more local estrogens and at the same time respond less to estradiol's protective signal. It is not enough to ask "how much estrogen is present"; the relevant questions are which estrogen dominates, where it is produced, and whether the tissue can still hear it.

Recent paper findings

Lee and den Hartigh (2025) update the framework: white adipose tissue is a metabolically relevant source of endogenous estrogens across the lifespan, with greater relative weight after menopause. Their review distinguishes the protective effect of E2 in healthy adipocytes from the possible dysfunctional role of E1 in contexts of aging, obesity, and insulin resistance. This corrects a common simplification: "more fat = more estrogen" does not equal "more estrogenic protection"; estrogen type, depot, and inflammatory state change the biological direction.

Ostinelli et al. (2022) show that women with metabolic dysfunction have increased adipose indices of androgen catabolism and aromatization, with CYP19A1 expression specifically higher in visceral adipose tissue. Iyengar et al. (2017) add a complementary finding: in postmenopausal women, aromatase in breast adipose tissue is associated with BMI, adipocyte diameter, local inflammation, IL-6, glucose, leptin, hsCRP, and HOMA2-IR; inflamed tissue also has higher aromatase than non-inflamed tissue even after considering BMI. The point is not only fat mass; it is dysfunctional adipose tissue.

Vidal et al. (2024) add the histone piece in women: insulin resistance is associated with greater histone lysine acetylation, chromatin opening at promoters of genes such as TNF and IL6, NFκB/TNFα signaling, innate immunity, senescence, and accelerated epigenetic aging in postmenopause. Although it is not an adipose-specific study, it provides the expected molecular signature in inflamed VAT: permissive chromatin for cytokines that can induce aromatase. Wu et al. (2025) closes the circuit: high-fat diet programs Esr1 methylation in adipocytes through DNMT1/DNMT3A, reduces ERα, increases adipose inflammation, and worsens insulin sensitivity; reversing Esr1 through epigenetic editing improves the phenotype. Lankila et al. (2025), in 124 menopausal women, confirms the systems layer: VAT mediates the relationship between health behaviours and GlycA, a signal of metabolic inflammation.

Full molecular/endocrine mechanism

The central node is a perimenopausal adipocyte that loses ovulatory E2 tone, receives higher insulin/cortisol/inflammatory load, and starts behaving like a low-resolution steroidogenic microgland. Its hormonal output does not replicate ovarian physiology; it generates local and systemic signals that are more continuous, less cyclic, and more VAT-dependent.

Adrenal DHEA-S / DHEA
        ↓ steroid sulfatase / 3β-HSD
Androstenedione ── CYP19A1 aromatase ──> Estrone (E1)
Testosterone     ── CYP19A1 aromatase ──> Estradiol (E2)
        ↓                                      ↓
HSD17B1/7/12 favor E1→E2              HSD17B2 favors E2→E1
        ↓                                      ↓
Local E1:E2 ratio in VAT/SAT          ERα/ERβ/GPER activation

The transcriptional decision for CYP19A1 is made through alternative promoters. In normal adipose stromal tissue, promoter I.4 responds to glucocorticoids and IL-6/IL-11/LIF/OSM-type cytokines through JAK/STAT3. In inflamed tissue, PGE2 activates EP1/EP2, cAMP, PKA/PKC, and promoters I.3/II. The microenvironment of hypertrophic VAT produces exactly these ligands.

Hypertrophic VAT / crown-like macrophages / local hypoxia
        ↓
TNFα + IL-6 + PGE2 + local cortisol
        ↓
NFκB + STAT3 + CREB + CBP/p300
        ↓
H3K9ac / H3K27ac at inflammatory genes and steroidogenic loci
        ↓
CYP19A1 ↑ in visceral stroma/adipose tissue
        ↓
Local E1 ↑ and non-cyclic estrogenic signaling

The problem becomes pathologically interesting when crossed with resistance to estrogenic signaling through receptor/chromatin mechanisms. The same obesogenic/inflammatory environment that can induce aromatase can also silence ERα in adipocytes. ERα normally favors insulin sensitivity, mitochondrial function, adiponectin, lower inflammation, and less visceral fat distribution. If Esr1/ESR1 becomes methylated or functionally repressed, the adipocyte can produce estrogens while losing protective responsiveness.

HFD / hyperinsulinemia / adipose inflammation
        ↓
DNMT1 + DNMT3A at the Esr1 promoter
        ↓
Adipocyte ERα ↓
        ↓
GLUT4 / adiponectin / mitochondrial oxidation ↓
NFκB / IL-6 / insulin resistance ↑
        ↓
Cytokines feeding CYP19A1 ↑

The histone layer adds a second gate. Vidal et al. observed greater H3K9ac/promoter opening in inflammatory genes among insulin-resistant women. Bitirim et al. show in a mesenchymal cell model that ERα can recruit EZH2 and increase H3K27me2/3 at adipogenic promoters such as PPARγ, C/EBPα, and Adipsin, acting as an epigenetic brake on adipogenesis. Extrapolated cautiously to perimenopausal adipose tissue: losing ERα tone could release adipogenic programs while inflammatory chromatin remains open.

E2 → ERα → EZH2 recruitment
                ↓
H3K27me2/3 at PPARγ / CEBPA / Adipsin
                ↓
Adipogenic brake and less dysfunctional expansion

Perimenopause + silenced ERα
                ↓
Lower H3K27me3 brake + higher inflammatory H3K9ac
                ↓
Inflammatory VAT, inducible aromatase, E1 dominance

My integrated reading: perimenopausal adipose tissue can enter an E1-high/ERα-low/H3K9ac-high state. That state explains why some women gain visceral fat, hot flashes, nighttime awakenings, reactive hunger, and metabolic fatigue even when peripheral hormone tests do not look dramatic. The problem is not one isolated hormone; it is tissue architecture.

Cross-synthesis with previous findings

Effective estrogenic signaling. ESR1/ESR2 methylation and receptor-ligand decoupling become more relevant when adding the tissue that can amplify that decoupling: an ERα-silenced adipocyte that produces local estrogens but loses protective responsiveness.
HPA-cortisol enters through CYP19A1. The adipose aromatase I.4 promoter responds to glucocorticoids and cytokines. Nocturnal cortisol and awakenings are not only symptoms; they can be molecular inputs. A mechanism appears here: cortisol + IL-6 can push adipose aromatase and remodel local estrogenic signaling.
Glucose-insulin enters through histones. Vidal et al. connect insulin resistance with histone acetylation, IL6/TNF, and senescence. Late meal patterns or glycemic load can be behavioral proxies of inflammatory chromatin, not only of energy/calories.
Menstrual chronobiology connects with adipose tissue. Loss of circadian amplitude and progesterone can increase awakenings, nighttime appetite, and worse glucose tolerance. This feeds VAT/insulin/cytokines, which in turn alters aromatase. There is a sleep-food-adipose-estrogen loop that the literature often treats in separate silos.
Microbiome and estrobolome add rather than compete. The estrobolome regulates estrogen deconjugation and recirculation; adipose tissue regulates local E1/E2 production. A woman can have altered estrogenic load from both ends: peripheral adipose production and intestinal recycling.

Lua Labs hypotheses

Hypothesis 52: Adipose Visceral Estrogen Switch

Statement: In women aged 42-58 years, a high/inflammatory VAT state with induced aromatase and silenced adipocyte ERα predicts hot flashes, awakenings, reactive hunger, and metabolic fatigue better than BMI or menopausal stage separately.

Proposed mechanism: The peri/postmenopausal window reduces cyclic ovarian E2 and increases dependence on adipose tissue for peripheral estrogens. If VAT is hypertrophic and insulin-resistant, IL-6/TNFα/PGE2/cortisol activate CYP19A1 promoters and open inflammatory chromatin. That tissue produces more E1/local estrogen, but at the same time HFD/IR/methylation reduce adipocyte ERα. The result is an estrogenic signal that is quantitatively present but qualitatively inefficient: more E1 and less protective ERα response. It should manifest as a metabolic-vasomotor symptom cluster, not as an isolated symptom.

Confidence level: Medium — each link has strong independent support; the full chain has not yet been longitudinally validated.

How to validate:

With a formal study: observational cohort of n=150-300 women aged 42-58, baseline waist/hip measurements, DEXA or MRI/ultrasound for VAT in a subsample, estrone, estradiol, testosterone, androstenedione, DHEA-S, insulin, HOMA-IR, hsCRP, IL-6, GlycA if available; daily symptom tracking for 12 weeks.

Limitations: Real VAT is not measured by dietary records; weight does not distinguish subcutaneous from visceral fat. MHT, contraceptives, PCOS, hypothyroidism, GLP-1 agonists, training changes, and diet can confound. Local adipose aromatase may not be reflected in serum, and peripheral E1/E2 have high analytical variability.

Hypothesis 53: H3K9ac meal-night flare

Statement: In perimenopause, late high-glycemic-load meals combined with poor sleep increase the probability of a vasomotor/metabolic flare 24-72 hours later by activating insulin-resistant inflammatory chromatin that feeds IL-6/PGE2/CYP19A1 in adipose tissue.

Proposed mechanism: Late eating reduces glucose tolerance by circadian phase, raises nocturnal insulin, and can reduce HRV/deep sleep. In women with vulnerable VAT, that metabolic pulse increases nuclear acetyl-CoA and pro-inflammatory signaling; Vidal et al. suggest that insulin resistance in women is accompanied by H3K9ac/promoter opening at IL6/TNF. IL-6 and PGE2 are precisely inputs into adipose aromatase. The hypothesis does not say that one meal acutely "raises estrogen"; it says that repeated patterns open the inflammatory-steroidogenic circuit that makes adipose tissue more endocrinologically noisy.

Confidence level: Medium-low — plausible and measurable, but histone-meal-symptom temporality requires direct validation.

How to validate:

With a formal study: crossover N-of-1 design in 40-60 perimenopausal women, two weeks of early/stable dinner vs two weeks of controlled late dinner, CGM, actigraphy, HRV, symptoms, and inflammatory markers before/after.

Limitations: Dietary records have registration error, and the effect can be confounded by alcohol, stress, cycle, ambient temperature, and physical activity. Histone acetylation is not measured directly through symptoms; it would be inferred through proxies.

Hypothesis 54: E1/receptor dissociation

Statement: A subgroup of peri/postmenopausal women with greater adipose aromatization may have relatively high estrone and still show symptoms of low effective estrogenic signaling because of adipocyte ERα resistance and inflammatory dominance.

Proposed mechanism: The literature often separates "estrogen deficiency" and "adipose estrogen excess." My proposal is that in dysfunctional adipose tissue both states coexist in different compartments: local/peripheral E1 can increase through CYP19A1, while adipocyte ERα falls because of methylation/epigenetic repression. The result is a signature of partial ligand abundance with reduced protective response. This could explain why some women with greater adiposity simultaneously have breast tenderness/fluid retention, hot flashes, insomnia, and metabolic resistance.

Confidence level: Medium — receptor-ligand decoupling is biologically coherent, but simultaneous phenotyping of E1/E2, adipose receptor state, and longitudinal symptoms is missing.

How to validate:

With a formal study: n=60 substudy with optional SAT biopsy for ESR1/CYP19A1, ESR1 methylation, H3K9ac/H3K27ac marks at inflammatory loci, together with E1/E2 and a digital diary.

Limitations: Estrone or local aromatase cannot be inferred from symptoms without biomarkers. It should be treated as a stratification hypothesis, not as a diagnosis.

Individual variability

The same fat mass does not imply the same hormonal effect. VAT/SAT distribution is central: visceral fat drains into the portal circulation, produces more cytokines, and is more associated with insulin resistance; gluteofemoral/subcutaneous fat may be less metabolically harmful. Two women with the same BMI can have very different aromatase, inflammation, and estrogenic response.

Genes and enzymes modify the E1/E2 ratio and tissue response. CYP19A1 defines aromatization capacity; HSD17B1/2/7/12 regulates E1/E2 interconversion; ESR1/ESR2 define receptor state; COMT, CYP1A1/CYP1B1, and methylation routes influence catechol-estrogen metabolism. MTHFR/folate/B12/SAM may modulate methylation capacity, although this should not be overreduced to a single SNP.

Environment and behavior enter as epigenetic regulators: sleep, meal timing, physical activity, alcohol, stress, xenoestrogen exposure, intestinal inflammation, and diet alter insulin, cortisol, IL-6/PGE2, and acetyl-CoA. Lankila et al. suggests that physical activity moderates the VAT-inflammation association in menopause; this fits the idea that adipose tissue is plastic, not fixed destiny.

Hormonal stage changes the context. In women with active cycles, the ovary still dominates much of the cyclic E2 signal; the adipose-aromatase axis would be secondary except in contexts of hyperinsulinemia or hyperandrogenism. In perimenopause, E2/progesterone variability creates windows where VAT and inflammation weigh more. In postmenopause, adipose and adrenal signaling can dominate the peripheral estrogenic landscape.